Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARLITE: Antiretrovirals and LITT for Unresectable High-Grade Gliomas
NCT06428045Phase 1Recruiting
- Sponsor
- University of Miami
- Start
- Apr 2025
- Primary completion
- Apr 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ritonavir, abacavir and lamivudine in glioma (2 cohorts), sponsored by University of Miami. Primary endpoints: Dose-Limiting Toxicity at 28 days and Serious Adverse Events and Grade 3 or Higher Adverse Events at 12 months. Started Apr 2025; status: recruiting.
02
Drugs
ritonavirabacavirlamivudine
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06428045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06428045.